Lisata Therapeutics' subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 trial of MAR002, a new antibody therapy for acromegaly, a rare hormone disorder. MAR002 targets the growth hormone receptor and showed promising Phase 1 results with potential for less frequent dosing than current treatments. The Phase 2 trial will enroll about 72 patients to evaluate the drug's effectiveness in reducing IGF-1 levels over 10 weeks, with an option for an open-label extension. This development could offer a transformative treatment option for patients who struggle with current therapies.
Lisata Therapeutics' subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. For readers following the health sector, here is Pluang's market snapshot as of Oct 05, 2026 20:33 WIB: of 100 priced Health-sector US stocks tradable on Pluang, 50 rose and 46 fell today. Notable movers include ABCL at USD 13.32 with a -3.06% change and a typical hold time of 41 days, DNA at USD 12.71 with a +2.96% change and a typical hold time of 8 days, and FLNA at USD 0.91 with a -2.23% change and a typical hold time of 37 days.
SPX Technologies (NYSE: SPXC) recently traded near its 52-week low around $170, down about 1.6% from the previous close. Despite this, several analysts maintain positive outlooks with price targets ranging from $250 to $301, indicating potential upsi...
PBF Energy's shares have surged 173% over the past year, nearing record highs due to stronger refining margins and improved quarterly results. The company reduced its net term debt by over $1.4 billion in Q2 2026, refinanced notes, and maintained nea...
J D Wetherspoon reported an 8.6% increase in like-for-like sales in the first nine weeks of its new financial year, helped by favorable weather. However, profit before tax fell 28% to £58.60 million despite a 5.2% revenue rise to £2.24 billion, mainl...
Oppenheimer has maintained its Outperform rating on Enphase Energy but lowered the price target from $56 to $55. Enphase Energy, a company specializing in solar microinverters, home batteries, and energy management products, has seen its shares drop ...
Broadcom's stock has surged about 25 times over the past decade, turning a $13 investment into $348. The company is now focusing on AI chips, expecting semiconductor revenue to reach $115 billion in fiscal 2027 and $230 billion in 2028. Despite a 29%...
